Duvic Madeleine, Bates Susan E, Piekarz Richard, Eisch Robin, Kim Youn H, Lerner Adam, Robak Tadeusz, Samtsov Alexey, Becker Jürgen C, McCulloch William, Waksman Joel, Whittaker Sean
a The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
b Department of Hematology/Oncology , Columbia University , New York , NY , USA.
Leuk Lymphoma. 2018 Apr;59(4):880-887. doi: 10.1080/10428194.2017.1361022. Epub 2017 Aug 30.
Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had ≥1 prior systemic therapy. Here, we present a subanalysis of two phase-2 trials (NCT00106431, NCT00007345) of romidepsin in patients with CTCL who had prior treatment with systemic chemotherapy. Patients with prior chemotherapy were able to achieve durable responses to romidepsin, and response rates were similar to those in patients who were chemotherapy naïve. Overall, no new safety signals emerged in patients who had received prior chemotherapy. The data presented here suggest that romidepsin is safe and effective in patients with CTCL who received prior systemic chemotherapy.
皮肤T细胞淋巴瘤（CTCL）是一组非霍奇金淋巴瘤，通常累及皮肤，但也可进展为全身受累。对于那些对全身化疗复发或难治的患者，最佳治疗方案仍不明确。罗米地辛是一种强效的I类选择性组蛋白脱乙酰酶抑制剂，已被批准用于治疗既往接受过≥1次全身治疗的CTCL患者。在此，我们对两项罗米地辛治疗既往接受过全身化疗的CTCL患者的2期试验（NCT00106431，NCT00007345）进行了亚组分析。既往接受过化疗的患者对罗米地辛能够产生持久反应，且缓解率与未接受过化疗的患者相似。总体而言，既往接受过化疗的患者未出现新的安全信号。此处呈现的数据表明，罗米地辛对于既往接受过全身化疗的CTCL患者是安全有效的。
